Log in

ASX:BD1 - BARD1 Life Sciences Stock Price, Forecast & News

0.00 (0.00 %)
(As of 12/16/2019 08:39 AM ET)
Today's Range
Now: A$0.04
50-Day Range
MA: A$0.04
52-Week Range
Now: A$0.04
Volume8.80 million shs
Average VolumeN/A
Market Capitalization$47.85 million
P/E RatioN/A
Dividend YieldN/A
BARD1 Life Sciences Limited focuses on developing and commercializing non-invasive diagnostic tests for early detection of cancer in Australia. It is developing BARD1 lung cancer test, a non-invasive blood test for screening and diagnosing lung cancer at early stages of disease progression. The company is also developing BARD1 ovarian cancer test, a non-invasive blood test for early detection of ovarian cancer. It has a collaboration agreement with Institute for Respiratory Health to evaluate a BARD1 cancer vaccine for the prevention and/or treatment of cancer in animal models; and Thermo Fisher Scientific to develop multiplex autoantibody assay. BARD1 Life Sciences Limited is headquartered in Nedlands, Australia.

Industry, Sector and Symbol

Industry Diagnostics & Research
Phone61 8 9381 9550



Sales & Book Value

Annual Sales$570,986.00
Cash FlowA$0.01 per share
Book ValueA$0.01 per share



Outstanding Shares1,367,190,016
Market Cap$47.85 million
Next Earnings DateN/A
OptionableNot Optionable

Receive BD1 News and Ratings via Email

Sign-up to receive the latest news and ratings for BD1 and its competitors with MarketBeat's FREE daily newsletter.

BARD1 Life Sciences (ASX:BD1) Frequently Asked Questions

What is BARD1 Life Sciences' stock symbol?

BARD1 Life Sciences trades on the ASX under the ticker symbol "BD1."

Has BARD1 Life Sciences been receiving favorable news coverage?

News headlines about BD1 stock have been trending somewhat negative on Monday, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. BARD1 Life Sciences earned a daily sentiment score of -1.7 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for BARD1 Life Sciences.

Who are some of BARD1 Life Sciences' key competitors?

Who are BARD1 Life Sciences' key executives?

BARD1 Life Sciences' management team includes the folowing people:
  • Mr. Peter Lynton Gunzburg B Comm, ASIA, Exec. Chairman & MD (Age 67)
  • Dr. Leearne Maree Hinch, Chief Exec. Officer
  • Dr. Irmgard Irminger-Finger, Founder, Exec. Director & Chief Scientific Officer
  • Ms. Pauline Anne Collinson, Company Sec.

What is BARD1 Life Sciences' stock price today?

One share of BD1 stock can currently be purchased for approximately A$0.04.

How big of a company is BARD1 Life Sciences?

BARD1 Life Sciences has a market capitalization of $47.85 million and generates $570,986.00 in revenue each year. BARD1 Life Sciences employs 5 workers across the globe.View Additional Information About BARD1 Life Sciences.

What is BARD1 Life Sciences' official website?

The official website for BARD1 Life Sciences is http://www.bard1.com/.

How can I contact BARD1 Life Sciences?

The company can be reached via phone at 61 8 9381 9550.

MarketBeat Community Rating for BARD1 Life Sciences (ASX BD1)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  6 (Vote Outperform)
Underperform Votes:  8 (Vote Underperform)
Total Votes:  14
MarketBeat's community ratings are surveys of what our community members think about BARD1 Life Sciences and other stocks. Vote "Outperform" if you believe BD1 will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BD1 will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/16/2019 by MarketBeat.com Staff

Featured Article: What is a conference call?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel